MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CGP48369

CAS No. : 135689-23-5

MCE 站：CGP48369

产品活性：CGP48369 是血管紧张素 II 受体 (angiotensin II receptor) 拮抗剂，用于研究抗高血压疾病。

研究领域：GPCR/G Protein

作用靶点：Angiotensin Receptor

In Vitro: CGP 48369 binds to the ATl receptor (IC₅₀ 1.8 nM in vascular smooth musc1e cells, VSMC) and inhibits AII-induced contraction in rabbit aorta (IC₅₀ 8.7 nM).

In Vivo: CGP48369 (10 mg/kg/day p.o.) decreases BP in two-kidney/one-clip renal hypertensive rats for at least 24 h. In arteries with endothelium, contractions induced by AII 3×10^-8 M do not differ in untreated spontaneously hypertensive rats (SHR) and WKY. All evoked significantly smaller contractions in SHR treated with CGP 48369 than in the other treated SHR. Antihypertensive treatment with benazepril or nifedipine, and to a lesser extent with CGP 48369, increases the sensitivity (pD2-va1ue) to intraluminal ACh. In arteries without endothelium, sensitivity to NE is identical in all groups, whereas maximal response in CGP 48369-treated SHR and in nifedipine treated SHR is slightly greater as compared with that in WKY. In SHR, antihypertensive therapy with either benazepril HCl, CGP 48369, valsartan, or nifedipine (each 10 mg/kg/d for 8 weeks) significantly increase endothelium-dependent relaxations evoked by acetylcholine.

相关产品：Angiotensin II human  |  Losartan  |  A 779  |  Telmisartan  |  PD 123319 ditrifluoroacetate  |  AVE 0991  |  Valsartan  |  Olmesartan  |  Tranilast  |  YS-49  |  Irbesartan  |  Candesartan  |  CGP-42112  |  Olodanrigan  |  Sparsentan  |  C-Type Natriuretic Peptide (CNP) (1-22), human  |  Azilsartan medoxomil  |  Angiotensin II 5-valine  |  Eprosartan mesylate  |  Angiotensin (1-7) (acetate)  |  Fimasartan  |  Tasosartan  |  Angiotensin II (3-8), human TFA

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。